Pure red cell aplasia as a complication of treatment with recombinant human erythropoietin
Grzegorzewska, A.E.; Sucharzewska-Tomczak, M.łg.
Polski Merkuriusz Lekarski Organ Polskiego Towarzystwa Lekarskiego 17(100): 407-409
2004
ISSN/ISBN: 1426-9686 PMID: 15690716 Document Number: 580341
Due to appearance in the world scientific literature of reports on occurrence of pure red cell aplasia (PRCA) as an adverse effect of treatment with recombinant human erythropoietin administered for anemia correction in the course of chronic renal failure, the paper presents rules of diagnosis and treatment of this complication. PRCA is more frequently observed during subcutaneous administration of erythropoietin a than erythropoietin beta. According to currently available analysis, prophylaxis of PRCA may include changing of the route of erythropoietin alpha administration from subcutaneous to intravenous one.